Best of ASCO 2022—bladder cancer

The Best Thing I Saw at ASCO

The 2017 American Society of Clinical Oncology (ASCO) annual meeting was a practice-changing event sure to excite even the most dispassionate among us. In my own field of gastrointestinal oncology, there were seismic alterations in the way many will now approach adjuvant therapy in colorectal and biliary tract cancers. And as we enter the brave newworld of histology agnosticism, even Kuhn would...

ASCO update: lung cancer

In the past few years there have been major changes in the treatment landscape in oncology; lung cancer is affected by those changes like almost no other solid tumor. The rise of further second- and third-line tyrosine kinase inhibitors offers sequential therapy for patients with mutated non-small-cell lung cancer. Immunotherapy has found its way into clinical routine and presents us with new c...

Best of ASCO ® Slovakia 2011 “ Place : Holiday Inn , Bratislava , Slovakia

ASCO 2017—highlights of gynecological cancer

At this year's ASCO annual meeting several important studies in the field of gynecological cancer were presented. Here we report a personal selection of the most interesting and clinically relevant data.

Highlights in breast cancer from ASCO 2016

A critical review of the highlights in breast cancer research from the American Society of Clinical Oncology (ASCO) meeting 2016, held in June 2016 in Chicago, is presented in this podcast. Considering the most interesting and practice-changing studies reported at the meeting, in the advanced breast cancer setting several important confirmatory studies on the use of CDK inhibitors, and studies ...